NIAID Funding News, February 3, 2021

February 3, 2021 NIAID Funding News Read this full edition online at http://www.niaid.nih.gov/grants-contracts/funding-news-notices Feature Articles  NIH or NIAID? Know the Difference Familiarize yourself with the differences between NIH and its institutes and centers as related to funding and peer review. Opportunities and Resources Get on TRAC With New Tuberculosis Funding Opportunity Support for Tuberculosis Research Advancement Centers (TRACs) will foster and enhance multidisciplinary collaboration across all aspects of tuberculosis research. Collaborate on Early Life Immune Development Research Through IDEaL Program Apply to study immune system development and maintenance in children from birth to adolescence, including the impact of pathogenic or non-pathogenic microbes or vaccination. In The News Budget Updates From January 2021 NIAID Advisory Council Meeting Learn more about NIH's $42.9 billion appropriation for fiscal year 2021, which is an increase in NIH's overall budget of $1.25 billion over the fiscal year 2020 level. Send Feedback To Inform NIAID's Approach on Key Immunologic Events in Autoimmune Diseases NIAID seeks comments from the scientific community about state-of-the-art sampling and analysis techniques to identify key immunologic events underlying the onset, flare, remission, and progression of autoimmune diseases. Advice Corner Find Your Score and More in the Summary Statement Your summary statement provides a summary of the study section's discussion, the recommended budget, and criterion scores from assigned reviewers. Reader Questions "If I relocate to another country, can I take my NIH funding with me?" "What is the minimum level of effort required on a grant?" New Funding Opportunities PAR-19-040, Countermeasures Against Chemical Threats (CounterACT)—Optimization of Therapeutic Lead Compounds (U01, Clinical Trial Optional) PAR-20-253, Countermeasures Against Chemical Threats (CounterACT)—Exploratory/Developmental Projects (R21, Clinical Trial Not Allowed) PAR-20-316, NIH Countermeasures Against Chemical Threats—Research Centers of Excellence (U54, Clinical Trial Optional) PAR-19-039, Countermeasures Against Chemical Threats (CounterACT)—Identification of Therapeutic Lead Compounds (U01, Clinical Trial Not Allowed) Find other announcements at NIAID Opportunities & Announcements. Send suggestions or comments to deaweb@niaid.nih.gov. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to rssproject471@gmail.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107

Tweet

Postingan terkait:

— Wednesday, February 3, 2021 — Add Comment